ODI Pharma (ODI) 주식 개요제약 회사인 ODI Pharma AB(publ)는 유럽에서 의약품용 대마초와 화장품을 생산 및 유통하는 회사입니다. 자세히 보기ODI 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6강점지난 5년 동안 수입이 매년 10% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(SEK71M)지난 3개월 동안 주가 변동성이 Swedish 시장과 비교해 높았습니다.의미 있는 수익이 없습니다(SEK20M)지난 1년 동안 주주가 희석되었습니다.모든 위험 점검 보기ODI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 3.8888.0% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8m242m2016201920222025202620282031Revenue SEK 241.5mEarnings SEK 35.3mAdvancedSet Fair ValueView all narrativesODI Pharma AB (publ) 경쟁사IRLAB TherapeuticsSymbol: OM:IRLAB AMarket cap: SEK 107.2mNewbury PharmaceuticalsSymbol: OM:NEWBRYMarket cap: SEK 42.6mPEPTONIC medicalSymbol: NGM:PMEDMarket cap: SEK 92.1mDouble Bond Pharmaceutical InternationalSymbol: NGM:DBP BMarket cap: SEK 12.9m가격 이력 및 성과ODI Pharma 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가SEK 3.8852주 최고가SEK 5.4552주 최저가SEK 1.00베타0.831개월 변동2.11%3개월 변동11.49%1년 변동50.39%3년 변동-29.45%5년 변동-18.32%IPO 이후 변동-54.57%최근 뉴스 및 업데이트Reported Earnings • Nov 29First quarter 2026 earnings released: kr0.002 loss per share (vs kr0.096 loss in 1Q 2025)First quarter 2026 results: kr0.002 loss per share (improved from kr0.096 loss in 1Q 2025). Revenue: kr6.00m (up kr5.85m from 1Q 2025). Net loss: kr37.1k (loss narrowed 98% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31Full year 2025 earnings released: kr0.32 loss per share (vs kr0.037 loss in FY 2024)Full year 2025 results: kr0.32 loss per share (further deteriorated from kr0.037 loss in FY 2024). Revenue: kr3.36m (down 85% from FY 2024). Net loss: kr5.88m (loss widened kr5.31m from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025New Risk • Jul 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Market cap is less than US$10m (kr27.3m market cap, or US$2.87m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.1m).New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue is less than US$1m (kr7.5m revenue, or US$786k). Market cap is less than US$10m (kr36.3m market cap, or US$3.78m).더 많은 업데이트 보기Recent updatesReported Earnings • Nov 29First quarter 2026 earnings released: kr0.002 loss per share (vs kr0.096 loss in 1Q 2025)First quarter 2026 results: kr0.002 loss per share (improved from kr0.096 loss in 1Q 2025). Revenue: kr6.00m (up kr5.85m from 1Q 2025). Net loss: kr37.1k (loss narrowed 98% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31Full year 2025 earnings released: kr0.32 loss per share (vs kr0.037 loss in FY 2024)Full year 2025 results: kr0.32 loss per share (further deteriorated from kr0.037 loss in FY 2024). Revenue: kr3.36m (down 85% from FY 2024). Net loss: kr5.88m (loss widened kr5.31m from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025New Risk • Jul 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Market cap is less than US$10m (kr27.3m market cap, or US$2.87m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.1m).New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue is less than US$1m (kr7.5m revenue, or US$786k). Market cap is less than US$10m (kr36.3m market cap, or US$3.78m).Reported Earnings • Feb 28Second quarter 2025 earnings released: kr0.17 loss per share (vs kr0.062 profit in 2Q 2024)Second quarter 2025 results: kr0.17 loss per share (down from kr0.062 profit in 2Q 2024). Revenue: kr74.0k (up kr72.9k from 2Q 2024). Net loss: kr2.56m (down 371% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공시 • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025공시 • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.공시 • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights OfferingNew Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (kr48.7m market cap, or US$4.46m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m).Reported Earnings • Nov 24First quarter 2025 earnings released: kr0.096 loss per share (vs kr0.095 loss in 1Q 2024)First quarter 2025 results: kr0.096 loss per share (further deteriorated from kr0.095 loss in 1Q 2024). Revenue: kr251.3k (down 52% from 1Q 2024). Net loss: kr1.47m (loss widened 1.8% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공시 • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공시 • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.공시 • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.공시 • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.공시 • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.공시 • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023공시 • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.공시 • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.공시 • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023공시 • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Jan 15ODI Pharma AB Proceeds with Its Plans and Launches Project SkinODI Pharma AB announced that the Board of Directors has decided to expand ODI's current business with specialized, highly CBD-infused skin care products. The Board of Directors sees Project Skin as a great platform to further build ODI Pharma's reputation and brand awareness. The products will be launched EU wide, with initial focus on a few markets, including Sweden. The Company will keep the market informed about the next step in the process.공시 • Nov 12ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020, at 10:00 Central European Standard Time. Location: Engelbrektsgatan 9-11 in Stockholm Stockholm Sweden Agenda: To consider Election of one or two persons to attest the minutes, where applicable; To consider Presentation of the annual report and auditor's report; To consider adoption of the income statement and the balance sheet and; To consider allocation of the company's profit or loss according to the adopted balance sheet; To consider discharge from liability for board members and the managing director; To consider amend the Articles of Association.공시 • Nov 03Odi Pharma AB and Aphria Inc. Execute Supply AgreementODI Pharma AB (publ) announced it has streamlined its supply chain and executed a Supply Agreement with Aphria Inc.'s wholly-owned German subsidiary, CC Pharma GmbH. The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward. The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names; ·The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland.Is New 90 Day High Low • Oct 29New 90-day low: kr4.61The company is down 5.0% from its price of kr4.83 on 29 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.주주 수익률ODISE PharmaceuticalsSE 시장7D1.6%2.7%1.9%1Y50.4%-8.2%12.3%전체 주주 수익률 보기수익률 대 산업: ODI은 지난 1년 동안 -8.2%의 수익을 기록한 Swedish Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: ODI은 지난 1년 동안 12.3%를 기록한 Swedish 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is ODI's price volatile compared to industry and market?ODI volatilityODI Average Weekly Movement12.7%Pharmaceuticals Industry Average Movement7.7%Market Average Movement6.3%10% most volatile stocks in SE Market13.2%10% least volatile stocks in SE Market3.7%안정적인 주가: ODI의 주가는 지난 3개월 동안 Swedish 시장보다 변동성이 컸습니다.시간에 따른 변동성: ODI의 주간 변동성은 지난 1년간 27%에서 13%로 감소했지만 여전히 Swedish 종목의 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트20181Jan-Mark Edewaardwww.odipharma.com제약 회사인 ODI Pharma AB(publ)는 유럽에서 의약품용 대마초와 화장품을 생산 및 유통하는 회사입니다. 말린 꽃과 칸돌 브랜드로 화장품 제품을 제공합니다. 이 회사는 2018년에 설립되었으며 스웨덴 스톡홀름에 본사를 두고 있습니다.더 보기ODI Pharma AB (publ) 기초 지표 요약ODI Pharma의 순이익과 매출은 시가총액과 어떻게 비교됩니까?ODI 기초 통계시가총액SEK 71.49m순이익 (TTM)-SEK 724.67k매출 (TTM)SEK 20.04m3.5x주가매출비율(P/S)-98.1x주가수익비율(P/E)ODI는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표ODI 손익계산서 (TTM)매출SEK 20.04m매출원가SEK 14.07m총이익SEK 5.97m기타 비용SEK 6.69m순이익-SEK 724.67k최근 보고된 실적Dec 31, 2025다음 실적 발표일May 28, 2026주당순이익(EPS)-0.04총이익률29.79%순이익률-3.62%부채/자본 비율0%ODI의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 22:04종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ODI Pharma AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Nov 29First quarter 2026 earnings released: kr0.002 loss per share (vs kr0.096 loss in 1Q 2025)First quarter 2026 results: kr0.002 loss per share (improved from kr0.096 loss in 1Q 2025). Revenue: kr6.00m (up kr5.85m from 1Q 2025). Net loss: kr37.1k (loss narrowed 98% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31Full year 2025 earnings released: kr0.32 loss per share (vs kr0.037 loss in FY 2024)Full year 2025 results: kr0.32 loss per share (further deteriorated from kr0.037 loss in FY 2024). Revenue: kr3.36m (down 85% from FY 2024). Net loss: kr5.88m (loss widened kr5.31m from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025
New Risk • Jul 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Market cap is less than US$10m (kr27.3m market cap, or US$2.87m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.1m).
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue is less than US$1m (kr7.5m revenue, or US$786k). Market cap is less than US$10m (kr36.3m market cap, or US$3.78m).
Reported Earnings • Nov 29First quarter 2026 earnings released: kr0.002 loss per share (vs kr0.096 loss in 1Q 2025)First quarter 2026 results: kr0.002 loss per share (improved from kr0.096 loss in 1Q 2025). Revenue: kr6.00m (up kr5.85m from 1Q 2025). Net loss: kr37.1k (loss narrowed 98% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31Full year 2025 earnings released: kr0.32 loss per share (vs kr0.037 loss in FY 2024)Full year 2025 results: kr0.32 loss per share (further deteriorated from kr0.037 loss in FY 2024). Revenue: kr3.36m (down 85% from FY 2024). Net loss: kr5.88m (loss widened kr5.31m from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025
New Risk • Jul 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Market cap is less than US$10m (kr27.3m market cap, or US$2.87m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.1m).
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue is less than US$1m (kr7.5m revenue, or US$786k). Market cap is less than US$10m (kr36.3m market cap, or US$3.78m).
Reported Earnings • Feb 28Second quarter 2025 earnings released: kr0.17 loss per share (vs kr0.062 profit in 2Q 2024)Second quarter 2025 results: kr0.17 loss per share (down from kr0.062 profit in 2Q 2024). Revenue: kr74.0k (up kr72.9k from 2Q 2024). Net loss: kr2.56m (down 371% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공시 • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025
공시 • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.
공시 • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights Offering
New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (kr48.7m market cap, or US$4.46m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m).
Reported Earnings • Nov 24First quarter 2025 earnings released: kr0.096 loss per share (vs kr0.095 loss in 1Q 2024)First quarter 2025 results: kr0.096 loss per share (further deteriorated from kr0.095 loss in 1Q 2024). Revenue: kr251.3k (down 52% from 1Q 2024). Net loss: kr1.47m (loss widened 1.8% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공시 • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024
Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공시 • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024
Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
공시 • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.
공시 • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024
Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
공시 • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024
Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
공시 • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023
공시 • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.
공시 • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023
Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
공시 • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023
공시 • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Jan 15ODI Pharma AB Proceeds with Its Plans and Launches Project SkinODI Pharma AB announced that the Board of Directors has decided to expand ODI's current business with specialized, highly CBD-infused skin care products. The Board of Directors sees Project Skin as a great platform to further build ODI Pharma's reputation and brand awareness. The products will be launched EU wide, with initial focus on a few markets, including Sweden. The Company will keep the market informed about the next step in the process.
공시 • Nov 12ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020, at 10:00 Central European Standard Time. Location: Engelbrektsgatan 9-11 in Stockholm Stockholm Sweden Agenda: To consider Election of one or two persons to attest the minutes, where applicable; To consider Presentation of the annual report and auditor's report; To consider adoption of the income statement and the balance sheet and; To consider allocation of the company's profit or loss according to the adopted balance sheet; To consider discharge from liability for board members and the managing director; To consider amend the Articles of Association.
공시 • Nov 03Odi Pharma AB and Aphria Inc. Execute Supply AgreementODI Pharma AB (publ) announced it has streamlined its supply chain and executed a Supply Agreement with Aphria Inc.'s wholly-owned German subsidiary, CC Pharma GmbH. The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward. The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names; ·The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland.
Is New 90 Day High Low • Oct 29New 90-day low: kr4.61The company is down 5.0% from its price of kr4.83 on 29 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
